MBTPS1 and inflammatory bowel disease: Inhibition of these transporters can effectively decrease S1P secretion, and these transporters have been considered a potential target for several immune disease therapies, such as that for IBD, multiple sclerosis and rheumatoid arthritis (Donoviel et al., 2015).